Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. LFTO
2. CMCSA
3. QNT
4. VRDN
5. NVDA
6. INIO
7. HONA
8. ABBV
9. HON
10. SPY

Go back to Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
(NASDAQ: CNTB) Delayed: 2.38 +0.19 (8.68%)
Previous Close $2.19    52 Week High $ 
Open $2.26    52 Week Low $ 
Day High $2.41    P/E N/A 
Day Low $2.16    EPS $ 
Volume 403,576